## **ARIC Manuscript Proposal #791**

PC Reviewed: <u>04/04/01</u>	Status: <u>A</u>	Priority: <u>N/A</u>
SC Reviewed:	Status:	Priority:

**1.a. Full Title:** Anti-cardiolipin antibodies (aCL) as a risk factor for venous thromboembolism (VTE) in a prospective study of healthy adults.

- b. Abbreviated Title (Length 26 characters): aCL and VTE risk in LITE
- 2. Writing Group (list individual with lead responsibility first):

Lead: Shauna Runchey Address: 648 Ontario St. SE Minneapolis, MN 55414

Phone: 612-676-1133 Fax: NA E-mail: runc0009@umn.edu Writing group members: Drs. A. Folsom, M Tsai, M. Cushman, P.McGovern

- 3. Timeline: March 2001 through June 2001
- 4. **Rationale:** This is part of the LITE (nested-case-control) ancillary study and serves as a MPH project.

While aCL have been shown to be a significant risk factor for VTE in case-control studies, primarily with underlying antiphospholipid antibody syndromes, this prospective study will address aCL as risk factor in healthy adults.

5. Main Hypothesis/Study Questions: There is a positive association between aCL and risk of venous thromboembolism in healthy adults. Study question 1: Independence of aCL as a risk factor for VTE. Study question 2: Linear trend of the association between aCL. Study question 3: Difference in risk association for IgG and IgM aCL.

## 6. Data (variables, time window, source, inclusions/exclusions): Dependent variable: VTE case-control status (n = 335) Covariates: Sex M,F Age years, at diagnosis Race BMI Factor VIII level Factor V Leiden status Independent variables: Level of IgG aCL Level of IgM aCL

Source: Data from laboratory analysis of blood and cohort records of Longitudinal Investigation of Thromboembolism Etiology (LITE) study.

Exclusions: Baseline history of anticoagulant therapy

- 7.a. Will the data be used for non-CVD analysis in this manuscript? \_\_\_\_\_ Yes \_\_\_\_\_ No
  - b. If Yes, is the author aware that the file ICTDER02 must be used to exclude persons with a value RES\_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis RES\_DNA = "CVD Research" would be used? \_\_\_\_\_ Yes \_\_\_\_\_ No (This file ICTDER02 has been distributed to ARIC PIs, and contains the responses to consent updates related to stored sample use for research.)
- 8.a. Will the DNA data be used in this manuscript? \_\_\_\_\_X\_ Yes \_\_\_\_No
- 8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER02 must be used to exclude those with value RES\_DNA = "No use/storage DNA"? \_\_\_\_\_X Yes \_\_\_\_No
- 9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at: http://bios.unc.edu/units/cscc/ARIC/stdy/studymem.html

\_\_\_\_x\_\_\_Yes \_\_\_\_\_No